Free Trial

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
73 shs
Average Volume
4.11 million shs
Market Capitalization
$3.73 billion
P/E Ratio
Dividend Yield
Price Target

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.08 Rating Score
11.8% Downside
$28.65 Price Target
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($1.38) to ($1.37) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.38 out of 5 stars

Medical Sector

876th out of 913 stocks

Pharmaceutical Preparations Industry

413th out of 429 stocks

CBAY stock logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CBAY Stock News Headlines

Gilead Sciences Completes Acquisition Of CymaBay Therapeutics
CBAY Jul 2024 34.000 call
CBAY Apr 2024 31.000 put
CBAY Oct 2024 33.000 call
CBAY Oct 2024 29.000 put
Maintaining Hold on CymaBay Amid Gilead Acquisition Deal Closure
CymaBay Therapeutics 4Q Loss/Shr 35c >CBAY
CBAY Jan 2026 37.000 call
CBAY Feb 2024 33.000 call
CBAY Jan 2025 8.000 put
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$31.07 million
Book Value
$2.58 per share


Free Float
Market Cap
$3.73 billion
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 11 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price target for 2024?

12 analysts have issued 1 year price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $15.00 to $32.50. On average, they predict the company's share price to reach $28.65 in the next year. This suggests that the stock has a possible downside of 11.8%.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) issued its quarterly earnings data on Wednesday, February, 28th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.31) by $0.04. The biopharmaceutical company earned $0.06 million during the quarter, compared to analysts' expectations of $0.42 million.

What ETFs hold CymaBay Therapeutics' stock?

ETFs with the largest weight of CymaBay Therapeutics (NASDAQ:CBAY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and AltShares Event-Driven ET (EVNT).AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC).

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Walleye Trading LLC (0.00%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Janet Dorling, Kurt Von Emster, Paul T Quinlan and Sujal Shah.
View institutional ownership trends

This page (NASDAQ:CBAY) was last updated on 6/12/2024 by Staff

From Our Partners